EMIG calls for action to build growth in the UK speciality biopharma sector

The UK Ethical Medicines Industry Group (EMIG) has called for government, the National Health Service, research bodies, regulatory authorities and industry to action a plan to strengthen R&D in the UK. The EMIG’s report, Achieving the Sustainable Growth of the Specialty Biopharmaceutical Sector in the UK, puts forward practical and tangible solutions to ensure the UK develops a strong, vibrant and sustainable operating environment for R&D, by particularly focusing on growth within the speciality biopharmaceutical sector.

The EMIG notes that, the sad but seemingly continued decline of the large pharmaceutical sector’s R&D footprint in the UK has sharpened attention on the business needs of smaller companies. In the UK, small and medium-sized enterprises (SMEs) constitute around 90% of the total number of biopharmaceutical companies and it is estimated that 80% of innovation is derived from these smaller companies.

SMEs crucial to innovation process